Figure 2. Incremental cost-effectiveness of the azithromycin (AZI) strategy compared with that of the doxycycline strategy, as the probability of the effectiveness of doxycycline is varied. The x-axis shows the effectiveness of doxycycline (base-case estimate, 0.857). The y-axis shows the additional cost incurred or saved for each additional major complication prevented. The solid curve represents the incremental cost-effectiveness of the azithromycin strategy relative to the doxycycline strategy. At rates of doxycycline effectiveness less than 0.93 (intersection of the solid curve and dotted line), the azithromycin strategy is a dominant one because it prevents more major complications and results in lower overall cost than the doxycycline strategy. At rates of doxycycline effectiveness higher than 0.93, the azithromycin strategy prevents more major complications than the doxycycline strategy but at a higher cost. The shaded area (0.80 to 0.90) represents the plausible range of doxycycline effectiveness for the population as a whole.

Return to article